Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of chemotherapy alone or combined with AMG 102 or panitumumab in first-line advanced or metastatic oesogastric adenocarcinoma
2009-012797-12Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jul 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of rilotumumab, panitumumab, oxaliplatin, folinic acid and fluorouracil in Gastroesophageal junction adenocarcinoma (GEJA), gastric cancer (GC), esophageal adenocarcinoma (EAC) and 1 more (3 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival rate at 4 months. Started Jul 2010; status: completed.
02
Drugs
rilotumumabpanitumumaboxaliplatinfolinic acidfluorouracil
03
Conditions
Gastroesophageal junction adenocarcinoma (GEJA)gastric cancer (GC)esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2009-012797-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012797-12.